Global Top ADC company

• ~ 2023

  • Platform

    ·Linker / PBD Toxins
    ·Conjugation

  • How We Do

    ·Monospecific Ab
    ·Cytotoxin payload

  • Business Model

    ·Early stage Out-licensing at the preclinical-IND stage

• ~ 2027

  • Platform

    ·Novel MoA Toxins
    ·I/O Payload

  • How We Do

    ·Bispecific Ab
    ·Novel Payload that spans multiple MOA
    · Combi with I/O payload

  • Business Model

    ·Value Inflection through clinical development of LCB’s own pipelines up to Phase 1/2

• ~ 2030

  • Platform

    ·Novel Ab/Ligand
    ·Linkers for non-cancer indications

  • How We Do

    ·Revolutionary ADC therapies that span beyond cancer - Immunotherapy, infectious disease, etc

  • Business Model

    ·Entering into late clinical and commercial stage of own pipeline ·Continued royalty revenue stream from partnered pipelines